Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interleukin 2].

T Taguchi, Y Kimoto

    Gan to Kagaku Ryoho. Cancer & Chemotherapy
    |May 1, 1987
    PubMed
    Summary

    Interleukin-2 (IL-2) alone has limited effectiveness against malignant diseases. Combining IL-2 with lymphokine-activated killer (LAK) cells is crucial for effective cancer immunotherapy, particularly for metastases.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    [The effect of CPT-11 in combination with interferon-alpha against human colon carcinoma heterotransplanted in nude mice: preliminary report].

    Nihon Geka Gakkai zasshi·1992
    Same author

    [Correlation of DBA lectin binding and malignancy in breast cancers: preliminary report].

    Nihon Geka Gakkai zasshi·1992
    Same author

    Pokeweed mitogen induces p55 interleukin-2 receptor expression on human monocytes and its effect on interleukin-2 activated monocyte cytotoxicity.

    Immunological investigations·1992
    Same author

    [Athyreotic congenital hypothyroidism in two sisters].

    Nihon Naibunpi Gakkai zasshi·1992
    Same author

    Immunological identification of a Cl- channel protein in electric organs of Narke japonica.

    Biochemical and biophysical research communications·1992
    Same author

    DNA synthesis and related enzymes altered in compensatory lung growth in rats.

    Scandinavian journal of clinical and laboratory investigation·1992

    Area of Science:

    • Immunology
    • Oncology
    • Biotherapy

    Context:

    • Malignant diseases present significant therapeutic challenges.
    • Current treatments for metastatic cancers require novel approaches.
    • Interleukin-2 (IL-2) is a cytokine with immunomodulatory properties.

    Purpose:

    • To evaluate the effectiveness of Interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells in treating malignant diseases.
    • To determine the necessity of combining IL-2 with LAK cells for enhanced anti-tumor activity.
    • To explore the potential applications of IL-2 and LAK cell therapy in managing metastatic cancers.

    Summary:

    • Systemic administration of IL-2 alone demonstrated limited efficacy against malignant diseases.
    • The combination of IL-2 with LAK cells is essential for LAK cells to effectively target and eliminate malignant cells.
    • Adoptive immunotherapy utilizing IL-2 and LAK cells shows promise for treating pulmonary and hepatic metastases.

    Impact:

    • This research highlights the synergistic potential of IL-2 and LAK cells in cancer treatment.
    • The findings suggest that combining IL-2 and LAK cell therapy with chemotherapy could be a future strategy.
    • Postoperative adjuvant therapy with IL-2 and LAK cells may improve outcomes for patients with metastatic disease.

    Related Experiment Videos